GlassScriptPhysician profile
Arjang Naim
NPI 1184614216
$9,725.31
in general payments reported to CMS, 2019-2025
23 companies · $671 in 2025
The $671 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,661 · 2020: $19.29 · 2021: $53.38 · 2022: $6,562 · 2023: $351 · 2024: $408 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,724.38 | 2019-2022 | |
| Myovant Sciences INC. | $151.05 | 2022 | |
| Pfizer INC. | $147.46 | 2022-2024 | |
| Abbvie INC. | $144.28 | 2020-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $143.42 | 2025 | Lumryz |
| Sumitomo Pharma America, INC. | $139.19 | 2023-2025 | Myfembree |
| Amgen INC. | $136.97 | 2024 | Repatha |
| Cook Medical LLC | $125.60 | 2019 | |
| Genzyme Corporation | $123.99 | 2025 | |
| Biogen, INC. | $122.95 | 2025 | Skyclarys |
| Teva Pharmaceuticals USA, INC. | $120.85 | 2024 | Austedo Xr |
| Madrigal Pharmaceuticals | $117.73 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $117.42 | 2022 | |
| Amarin Pharma, INC. | $117.36 | 2023 | |
| Shield Therapeutics INC | $83.82 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $49.67 | 2021-2024 | Thinprep 2000 Processor, Aptima |
| Medicem INC. | $33.18 | 2021 | |
| Lilly USA, LLC | $26.27 | 2025 | Mounjaro |
| Evofem Biosciences, INC. | $24.60 | 2022 | |
| Astellas Pharma US INC | $22.58 | 2023 | Veozah |
| Lupin INC. | $18.60 | 2019 | |
| Exeltis, USA INC. | $17.00 | 2023 | Slynd |
| Allergan, INC. | $16.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjang Naim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.